Details for Patent: 9,492,316

Which drugs does patent 9,492,316 protect, and when does it expire?

Patent 9,492,316 protects DURYSTA and is included in one NDA.

This patent has fifty patent family members in twenty-nine countries.

Summary for Patent: 9,492,316

Title:	Prostamide-containing intraocular implants and methods of use thereof
Abstract:	Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
Inventor(s):	Ghebremeskel; Alazar N. (Irvine, CA), Robinson; Michael R. (Irvine, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	14/529,526
Patent Claim Types: see list of patent claims	Use; Formulation; Compound; Process; Delivery; Device;

Drugs Protected by US Patent 9,492,316

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	DURYSTA	bimatoprost	IMPLANT;OPHTHALMIC	211911-001	Mar 4, 2020		RX	Yes	Yes			Y

International Family Members for US Patent 9,492,316

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014342017
Australia	2020201778
Australia	2022200742
Brazil	112016009575
Canada	2926515